Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

BACKGROUND: Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg. METHODS: ODYSSEY is an open-label, randomised, non-inferiority trial (10% margin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet HIV 2022-09, Vol.9 (9)
Hauptverfasser: Amuge, Pauline, Lugemwa, Abbas, Wynne, Ben, Mujuru, Hilda A, Violari, Avy, Kityo, Cissy M, Archary, Moherndran, Variava, Ebrahim, White, Ellen, Turner, Rebecca M, Shakeshaft, Clare, Ali, Shabinah, Nathoo, Kusum J, Atwine, Lorna, Liberty, Afaaf, Bbuye, Dickson, Kaudha, Elizabeth, Mngqibisa, Rosie, Mosala, Modehei, Mumbiro, Vivian, Nanduudu, Annet, Ankunda, Rogers, Maseko, Lindiwe, Kekitiinwa, Adeodata R, Giaquinto, Carlo, Rojo, Pablo, Gibb, Diana M, Turkova, Anna, Ford, Deborah, ODYSSEY Trial Team
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND: Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg. METHODS: ODYSSEY is an open-label, randomised, non-inferiority trial (10% margin) comparing dolutegravir-based ART with standard of care and comprises two cohorts (children weighing ≥14 kg and
ISSN:2405-4704
DOI:10.1016/s2352-3018(22)00163-1